Fabino Enterprises Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Fabino Enterprises Ltd is ₹ 20.31 as of 27 Apr 15:30 . The p/e ratio of Fabino Enterprises Ltd changed from 600 to 84.5 over 3 quarters. This represents a CAGR of -92.67% The p/e ratio of Sanofi India Ltd changed from 30.8 to 0 over 5 quarters. This represents a CAGR of -100.00% The market cap of Fabino Enterprises Ltd changed from ₹ 6.3 crore to ₹ 5.15 crore over 3 quarters. This represents a CAGR of -23.57% The market cap of Sanofi India Ltd changed from ₹ 18578 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00% The Revenue of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Fabino Enterprises Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Fabino Enterprises Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Fabino Enterprises Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Fabino Enterprises Ltd or Sanofi India Ltd?

Market cap of Fabino Enterprises Ltd is 4 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Fabino Enterprises Ltd and Sanofi India Ltd?

The stock performance of Fabino Enterprises Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fabino Enterprises Ltd and Sanofi India Ltd?

As of May 6, 2026, the Fabino Enterprises Ltd stock price is INR ₹20.31. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Fabino Enterprises Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Fabino Enterprises Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.